Ghanashyam Acharya

Dr. Ghanashyam Acharya

Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USA
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
GAGhanashyam Acharya
Ghanashyam Acharya
KPKinam Park
Kinam Park

13 January 2015 in ACS Nano
Verified
Journal Article
Open access
XYXiaoyong Yuan
Xiaoyong Yuan
DMDaniela C. Marcano
Daniela C. Marcano
CSCrystal S. Shin
Crystal S. Shin
XHXia Hua
Xia Hua
LILucas C. Isenhart
Lucas C. Isenhart
GAGhanashyam Acharya
Ghanashyam Acharya
Presently, eye injuries are treated by topical eye drop therapy. Because of the ocular surface barriers, topical eye drops must be applied several times in a day, causing side effects such as glaucoma, cataract, and poor patient compliance. This article presents the development of a nanowafer drug delivery system in which the polymer and the drug work synergistically to elicit an enhanced therapeutic efficacy with negligible adverse immune responses. The nanowafer is a small transparent circular disc that contains arrays of drug-loaded nanoreservoirs. The slow drug release from the nanowafer increases the drug residence time on the ocular surface and its subsequent absorption into the surrounding ocular tissue. At the end of the stipulated period of drug release, the nanowafer will dissolve and fade away. The in vivo efficacy of the axitinib-loaded nanowafer was demonstrated in treating corneal neovascularization (CNV) in a murine ocular burn model. The laser scanning confocal imaging and RT-PCR study revealed that once a day administered axitinib nanowafer was therapeutically twice as effective, compared to axitinib delivered twice a day by topical eye drop therapy. The axitinib nanowafer is nontoxic and did not affect the wound healing and epithelial recovery of the ocular burn induced corneas. These results confirmed that drug release from the axitinib nanowafer is more effective in inhibiting CNV compared to the topical eye drop treatment even at a lower dosing frequency.

1 July 2003 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
JLJaehwi Lee
Jaehwi Lee
SLSang Cheon Lee
Sang Cheon Lee
GAGhanashyam Acharya
Ghanashyam Acharya
CCChing-Jer Chang
Ching-Jer Chang
KPKinam Park
Kinam Park

1 February 2010 in Journal of Controlled Release
Verified
Journal Article
Closed access
GAGhanashyam Acharya
Ghanashyam Acharya
CSCrystal S. Shin
Crystal S. Shin
MMMatthew McDermott
Matthew McDermott
HMHimanshu Mishra
Himanshu Mishra
HPHaesun Park
Haesun Park
KPKinam Park
Kinam Park

1 August 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
FCFernando J. Cabrera
Fernando J. Cabrera
DWDaniel C. Wang
Daniel C. Wang
KRKartik Reddy
Kartik Reddy
GAGhanashyam Acharya
Ghanashyam Acharya
CSCrystal S Shin
Crystal S Shin

1 December 2008 in Journal of Controlled Release
Verified
Journal Article
Closed access
SKSungwon Kim
Sungwon Kim
JKJi Young Kim
Ji Young Kim
KHKang Moo Huh
Kang Moo Huh
GAGhanashyam Acharya
Ghanashyam Acharya
KPKinam Park
Kinam Park